関節内補充療法用医療機器：企業動向...市場調査レポートについてご紹介

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Treatment Modalities Overview
3.1 Treatment Paradigm
3.1.1 Physical Therapies
3.1.2 Medications
3.1.3 Hyaluronic Acid Viscosupplementation
3.1.4 Surgical Intervention
4 Competitive Assessment
4.1 Major Viscosupplementation Products
4.1.1 Adant
4.1.2 Arthrum
4.1.3 Curavisc
4.1.4 Durolane
4.1.5 Euflexxa
4.1.6 Fermathron
4.1.7 Gel-One
4.1.8 Go-On
4.1.9 Hyalgan
4.1.10 Hyalubrix and HyalOne
4.1.11 Jonexa
4.1.12 NeoVisc
4.1.13 Orthovisc and Monovisc
4.1.14 Ostenil
4.1.15 Recosyn
4.1.16 RenehaVis
4.1.17 Supartz/ARTZ
4.1.18 Suplasyn
4.1.19 Suvenyl
4.1.20 Synocrom
4.1.21 Synolis V-A
4.1.22 Synovial
4.1.23 Synvisc and Synvisc-One
4.2 Other Viscosupplementation Products
5 Pipeline Products
5.1 Overview
5.2 Gel-Syn (IBSA Institut Biochimique S.A.)
5.3 Cingal (Anika Therapeutics)
5.4 Hydros-TA (Carbylan Therapeutics)
5.5 Additional Indication for Synvisc-One (Sanofi)
5.6 Hymovis (Fidia Farmaceutici S.p.A.)
5.7 HA-NSAID Conjugates (Seikagaku Corporation)
5.8 Additional Indication for Supartz/ARTZ (Seikagaku Corporation)
5.9 Clodronate-HA Conjugates (Abiogen Pharma)
6 Current and Future Players
6.1 Trends in Corporate Strategy
6.2 Major Manufacturers
6.2.1 Anika Therapeutics
6.2.2 Chugai Pharmaceutical
6.2.3 Ferring Pharmaceuticals
6.2.4 Fidia Farmaceutici S.p.A.
6.2.5 Meda AB
6.2.6 Sanofi
6.2.7 Seikagaku Corporation
6.3 Major Marketing Partners
6.3.1 Bioventus
6.3.2 DePuy Synthes
6.3.3 Zimmer-Biomet
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Report Methodology
7.3.1 Overview
7.3.2 Coverage
7.3.3 Secondary Research
7.3.4 Forecasting Methodology
7.3.5 Primary Research — Key Opinion Leader Interviews
7.3.6 Expert Panel Validation
7.4 Physicians and Specialists Included in This Study
7.5 About the Authors
7.5.1 Analysts
7.5.2 Jim Coutcher, MS, Global Head of Healthcare
7.6 About MediPoint
7.7 About GlobalData
7.8 Contact Us
7.9 Disclaimer